Pharma seeks to offload old drugs

Share this article:

The industry merry-go-round of sales and swaps continues to spin. The Wall Street Journal reports that Sanofi, Merck and GlaxoSmithKline are independently exploring ways to offload their portfolios of older drugs. Insiders tell the Journal that Merck has been chatting up possible buyers of a series of drugs for about $15 billion, and that Sanofi is thinking of a joint venture to house some of its mature products.

GlaxoSmithKline, which recently participated in an asset swap with Novartis is also said to be contemplating divestment of older products.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.